Beloranib reduces weight in Prader-Willi syndrome, but concerns remain

BOSTON – Prader-Willi syndrome patients lost more than 4% of their body weight over a 26-week period with the investigative antiobesity drug beloranib, compared with a similar gain in patients taking...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news